Herpes vaccine candidate
BCHT HSV-2 mRNA vaccine
phase 1 Changchun BCHT Biotechnology Co.
Last updated:
BCHT HSV-2 mRNA vaccine is an mRNA vaccine candidate for HSV-2, developed by Changchun BCHT. Development phase: phase 1. Phase 1 dose-escalation safety trial of an mRNA vaccine, enrolling by invitation. No results posted.
Page last updated . ClinicalTrials.gov data as of .
| Developer | Changchun BCHT Biotechnology Co. |
|---|---|
| Platform | mRNA |
| HSV target | HSV-2 |
| Approach | unclear |
| Phase | phase 1 |
| Status | A Phase 1 dose-escalation trial started in 2025 and is enrolling by invitation, with primary completion listed for 2027; no results are posted. |
| Trials | NCT07330440 |
This is an mRNA vaccine against HSV-2 whose registered trial is sponsored by Changchun BCHT Biotechnology Co. Its phase 1 dose-escalation trial, NCT07330440, is evaluating safety, tolerability and immunogenicity in healthy participants aged 18-55, stratified by serostatus. As of the 2026-09-27 registry search, that trial was the one record found and was enrolling by invitation, with no results posted.
What the BCHT HSV-2 mRNA vaccine is
The registry describes it as an mRNA vaccine against herpes simplex virus type 2 (HSV-2), with Changchun BCHT Biotechnology Co. as lead sponsor. The sources do not name the HSV-2 proteins the mRNA encodes.
Where the BCHT HSV-2 mRNA vaccine stands
NCT07330440 is a phase 1 dose-escalation study of safety, tolerability and immunogenicity. It is in healthy participants aged 18-55, stratified by serostatus, and lists genital herpes as the condition. The record lists low-, mid- and high-dose cohorts and a placebo group. Its status is enrolling by invitation, with an estimated enrollment of 144 and a start in 2025. The registry lists primary completion for 2027; this is a planned date, not a result. A ClinicalTrials.gov search on 2026-09-27 for records naming the vaccine returned 1 record, this trial, which had an ongoing status.
What this does and doesn’t mean for the BCHT HSV-2 mRNA vaccine
A phase 1 trial being under way shows the vaccine is being tested in people, not that it works; its stated aims are safety, tolerability and immunogenicity. No results are posted on the registry.
Registry snapshot
- Registry status
- Enrolling by invitation
- Phase
- phase 1
- Enrollment
- 144 (estimated)
- Lead sponsor
- Changchun BCHT Biotechnology Co.
- Started
- Oct 13, 2025
- Primary completion
- Mar 4, 2027
Registry record last updated Jan 9, 2026.
Sources
- ClinicalTrials.gov registry search for BCHT HSV mRNA vaccine (searched 2026-09-27)
- A Phase I, Dose-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) in Healthy Participants Aged 18-55 Years, Stratified by Serostatus (NCT07330440)